Skip to main content
HealthReportedHighFeatured
7.2

FDA rejects Summit Therapeutics' lung cancer drug ivonescimab

The FDA has rejected ivonescimab, a bispecific antibody for non-small cell lung cancer developed by Summit Therapeutics and China's Akeso. The rejection is a major setback for Summit, which had bet heavily on the drug's approval. The decision raises uncertainty about the drug's regulatory path and its competitive position against existing PD-1 inhibitors.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works

STAT Newsabout 17 hours agoUS, CNengCredibility 18%View source

Score Breakdown

Mosaic Score7.2
Model confidence0.9
Significance0.8
Source credibility0.2

Intelligence Tags

Entities

United StatescountryChinacountry
Source

Related signals

8 found